Reach Us
Niir Project Consultancy Services (NPCS)
AN ISO 9001 : 2015 CERTIFIED COMPANY
106-E, Kamla Nagar,Opposite Spark Mall,
New Delhi-110007, India.
Email: npcs.ei@gmail.com,
info@entrepreneurindia.co
Tel: 91-11-23843955, 23845654, 23845886, +91-8800733955
Mobile: +91-9811043595
Fax: 91-11-23845886
Web: www.entrepreneurindia.co
  • Join Us On
Reach Us
Quick Enquiry
 
   
   
Quick Enquiry
Add to wishlist Add to cart Add to inquiry Buy now Download page as pdf

Global Precision Medicine Market (2018-2023) ( ) ( )

Author Netscribes ISBN -
Code ENI473 Format CD-Rom
Price: Rs 299925   299925 + Tax @ 18.00 % US$ 3999   3999
Pages: 100 Published 2018
Publisher Netscribes  
Usually Ships within 5

"Global Precision Medicine Market


Precision medicine is an upcoming approach which involves investigating whether a person has any diseases by evaluating the genetic makeup, and then diagnosing it. According to Netscribes, the global precision medicine market is expected to have a significant compounded annual growth rate (CAGR) of 9.7% and have a market size in excess of USD 96 Bn by 2023. North America dominates the global market due to the high incidence of cancer and increasing government initiatives in the region.

Precision medicine involves a study of patient specific information to diagnose, and then categorize various diseases. The concept of precision medicine is rapidly growing in the medicine community through tremendous expansion in various advanced technologies, such as next-generation sequencing, molecular biomarker analysis, and much more. With the help of growing technologies, precision medicine plays a vital role in preventing and treating various diseases such as cancer, cardiovascular, neurology and other diseases, which are currently burdening the healthcare system.


The global precision medicine market is classified into three primary segments - based on end use: pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies; based on therapeutics: cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases; and based on sub-market: big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics.


Key growth factors


The concept of precision medicine has gained momentum in the healthcare community, powered by the tremendous expansion of various advanced technologies such as next-generation sequencing, molecular biomarker analysis and many more. Technological advancements have helped the precision medicine market prevent as well as treat diseases such as cancer, cardiovascular, neurology, diabetes, and others.

Rising pressure to lower healthcare cost globally, growth of personal healthcare devices, the emergence of value-based reimbursement models, and healthcare digitization trends are aiding the transition of treatment model from ‘one-size-fits-all’ to stratified and outcome-based targeted therapies, which are called precision medicine.


Threats and key players


Threat to personal data, high diagnostic costs, and the risk of hardware and software failure are some of the factors that will hinder the growth of the market.

The key players that have been contributing significantly to the precision medicine market include Abbott Laboratories, GE Healthcare, GlaxoSmithKline (GSK), Johnson & Johnson, Pfizer, Laboratories Corporation of America Holdings and Danaher Corporation, among others.


What’s covered in the report?


1. Overview of the global precision medicine market

2. Market Drivers and challenges in the global precision medicine market.

3. Market Trends in the global precision medicine market

4. Historical, current and forecasted market size data for end use segment in the global precision medicine market (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies)

5. Historical, current and forecasted market size data for the therapeutics segment in the global precision medicine market (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)

6. Historical, current and forecasted market size data for the sub-market segment in the global precision medicine market (big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics)

7. Analysis of the competitive landscape and profiles of major companies operating in the market


Why buy?


1. Get a broad understanding of the global precision medicine market, end uses, therapeutics, and the other sub-markets

2. Get geography-specific drivers and challenges affecting the global precision medicine market, its end uses, therapeutics, and the sub-markets 

3. Devise market-entry strategies by understanding the factors driving the growth of the market

4. Identify the challenges and address them

5. Get insights into the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth


Customizations Available


With the given market data, Netscribes offers customizations according to specific needs. Write to us at info@netscribes.com.

"

 

 Chapter 1: Executive summary
1.1. Market scope and segmentation
1.2. Key questions answered in this study
1.3. Executive Summary

Chapter 2: Global precision medicine market - market overview
2.1. Global market overview - market trends, market attractiveness analysis, geography-wise market revenue (USD)
2.2. Global market drivers and challenges
2.3. Value chain analysis – precision medicine market
2.4. Porter’s Five Forces Analysis
2.5. Market segmentation based on end use (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)
2.5.  a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5.  b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5.  c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5.  d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. Market segmentation for therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)
2.6.  a. Revenue from cancer therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6.  b. Revenue from cardiovascular therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6.  c. Revenue from central nervous system therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6.  d. Revenue from psychiatric disorder therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6.  e. Revenue from infectious diseases therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. Market segmentation based on sub-market (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)
2.7.  a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7.  b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7.  c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7.  d. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7.  e. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 3: North America precision medicine market - market overview
3.1. Market overview - market trends, market attractiveness analysis, geography wise market revenue (USD)
3.2. North America - market drivers and challenges
3.3. Market segmentation based on end use (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)
3.3.  a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.  b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.  c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3.  d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. Market segmentation based on therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)
3.4.  a. Revenue from cancer therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4.  b. Revenue from cardiovascular therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4.  c. Revenue from central nervous system therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4.  d. Revenue from psychiatric disorder therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4.  e. Revenue from infectious diseases therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.5. Market segmentation based on sub-market (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)
3.5.  a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.5.  b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.5.  c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.5.  d. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.5.  e. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 4: Europe precision medicine market- market overview
4.1. Market overview - market trends, market attractiveness analysis, geography wise market revenue (USD)
4.2. Europe - market drivers and challenges
4.3. Market segmentation based on end use (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)
4.3.  a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3.  b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3.  c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3.  d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. Market segmentation based on therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)
4.4.  a. Revenue in cancer therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4.  b. Revenue from cardiovascular therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4.  c. Revenue from central nervous system therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4.  d. Revenue from psychiatric disorder therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4.  e. Revenue from infectious diseases therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.5. Market segmentation based on sub-market (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)
4.5.  a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.5.  b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.5.  c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.5.  d. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.5.  e. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 5: Asia-Pacific precision medicine market - market overview
5.1. Market overview - market trends, market attractiveness analysis, geography wise market revenue (USD)
5.2. Asia-Pacific - market drivers and challenges
5.3. Market segmentation based on end use (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)
5.3.  a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3.  b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3.  c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3.  d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. Market segmentation based on therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)
5.4.  a. Revenue from cancer therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4.  b. Revenue from cardiovascular therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4.  c. Revenue from central nervous system therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4.  d. Revenue from psychiatric disorder therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4.  e. Revenue from infectious diseases therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.5. Market segmentation based on sub-market (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)
5.5.  a. Revenue from big data analytics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.5.  b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.5.  c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.5.  d. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.5.  e. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 6: Latin America precision medicine market - market overview
6.1. Market overview - market trends, market attractiveness analysis, geography wise market revenue (USD)
6.2. Latin America - market drivers and challenges
6.3. Market segmentation based on end use (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)
6.3.  a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
6.3.  b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
6.3.  c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
6.3.  d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
6.4. Market segmentation based on therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)
6.4.  a. Revenue from cancer therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
6.4.  b. Revenue from cardiovascular therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
6.4.  c. Revenue from central nervous system therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
6.4.  d. Revenue from psychiatric disorder therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
6.4.  e. Revenue from infectious diseases therapeutics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
6.5. Market segmentation based on sub-market (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)
6.5.  a. Revenue from big data analytics- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
6.5.  b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
6.5.  c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
6.5.  d. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
6.5.  e. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 7: Middle East and Africa precision medicine market - market overview
7.1. Market overview-market trends, market attractiveness analysis, geography wise market revenue (USD)
7.2. Middle East and Africa - market drivers and challenges
7.3. Market segmentation based on end use (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies, healthcare IT specialists/big data companies)
7.3.  a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
7.3.  b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
7.3.  c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
7.3.  d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
7.4. Market segmentation based on therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder, infectious diseases)
7.4.  a. Revenue from cancer therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
7.4.  b. Revenue from cardiovascular therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
7.4.  c. Revenue from central nervous system therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
7.4.  d. Revenue from psychiatric disorder therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
7.4.  e. Revenue from infectious diseases therapeutics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
7.5. Market segmentation based on sub-market (big data analytics, bioinformatics, gene sequencing, pharmacogenomics, companion diagnostics)
7.5.  a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
7.5.  b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
7.5.  c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
7.5.  d. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
7.5.  e. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 8: Competitive landscape
8.1. Abbott Laboratories
8.1.  a. Company snapshot
8.1.  b. Product offerings
8.1.  c. Growth strategies
8.1.  d. Initiatives
8.1.  e. Geographical presence
8.1.  f. Key numbers
8.2. GE Healthcare
8.2.  a. Company snapshot
8.2.  b. Product offerings
8.2.  c. Growth strategies
8.2.  d. Initiatives
8.2.  e. Geographical presence
8.2.  f. Key numbers
8.3. GlaxoSmithKline (GSK)
8.3.  a. Company snapshot
8.3.  b. Product offerings
8.3.  c. Growth strategies
8.3.  d. Initiatives
8.3.  e. Geographical presence
8.3.  f. Key numbers
8.4. Johnson & Johnson
8.4.  a. Company snapshot
8.4.  b. Product offerings
8.4.  c. Growth strategies
8.4.  d. Initiatives
8.4.  e. Geographical presence
8.4.  f. Key numbers
8.5. Pfizer
8.5.  a. Company snapshot
8.5.  b. Product offerings
8.5.  c. Growth strategies
8.5.  d. Initiatives
8.5.  e. Geographical presence
8.5.  f. Key numbers
8.6. Randox Laboratories
8.6.  a. Company snapshot
8.6.  b. Product offerings
8.6.  c. Growth strategies
8.6.  d. Initiatives
8.6.  e. Geographical presence
8.6.  f. Key numbers
8.7. Almac Group
8.7.  a. Company snapshot
8.7.  b. Product offerings
8.7.  c. Growth strategies
8.7.  d. Initiatives
8.7.  e. Geographical presence
8.7.  f. Key numbers
8.8. Novartis AG
8.8.  a. Company snapshot
8.8.  b. Product offerings
8.8.  c. Growth strategies
8.8.  d. Initiatives
8.8.  e. Geographical presence
8.8.  f. Key numbers
8.9. Teva Pharmaceuticals Limited
8.9.  a. Company snapshot
8.9.  b. Product offerings
8.9.  c. Growth strategies
8.9.  d. Initiatives
8.9.  e. Geographical presence
8.9.  f. Key numbers
8.10. CETICS Healthcare Technologies GmbH
8.10.  a. Company snapshot
8.10.  b. Product offerings
8.10.  c. Growth strategies
8.10.  d. Initiatives
8.10.  e. Geographical presence
8.10.  f. Key numbers

Chapter 9: Conclusion

Chapter 10: Appendix
10.1 List of tables
10.2 Research methodology
10.3 About Netscribes Inc.

Note: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research. The report is in progress and will be delivered within 12 business days post payment confirmation


COMPANIES COVERED
o Abbott Laboratories
o GE Healthcare
o GlaxoSmithKline (GSK)
o Johnson & Johnson
o Pfizer
o Randox Laboratories
o Almac Group
o Novartis AG
o Teva Pharmaceuticals Limited
o CETICS Healthcare Technologies GmbH

 

 

ABOUT NPCS

 

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report,  Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Section of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

Our Detailed Project report aims at providing all the critical data required by any entrepreneur vying to venture into Project. While expanding a current business or while venturing into new business, entrepreneurs are often faced with the dilemma of zeroing in on a suitable product/line.

 


And before diversifying/venturing into any product, wish to study the following aspects of the identified product:


• Good Present/Future Demand
• Export-Import Market Potential
• Raw Material & Manpower Availability
• Project Costs and Payback Period


We at NPCS, through our reliable expertise in the project consultancy and market research field, Provides exhaustive information about the project, which satisfies all the above mentioned requirements and has high growth potential in the markets. And through our report we aim to help you make sound and informed business decision.

 

The report contains all the data which will help an entrepreneur find answers to questions like:

• Why I should invest in this project?
• What will drive the growth of the product?
• What are the costs involved?
• What will be the market potential?


The report first focuses on enhancing the basic knowledge of the entrepreneur about the main product, by elucidating details like product definition, its uses and applications, industry segmentation as well as an overall overview of the industry sector in India. The report then helps an entrepreneur identify the target customer group of its product. It further helps in making sound investment decision by listing and then elaborating on factors that will contribute to the growth of product consumption in India and also talks about the foreign trade of the product along with the list of top importing and top exporting countries. Report includes graphical representation and forecasts of key data discussed in the above mentioned segment. It further explicates the growth potential of the product.

The report includes other market data like key players in the Industry segment along with their contact information and recent developments. It includes crucial information like raw material requirements, list of machinery and manufacturing process for the plant. Core project financials like plant capacity, costs involved in setting up of project, working capital requirements, projected revenue and profit are further listed in the report.


Reasons for buying the report:

• This report helps you to identify a profitable project for investing or diversifying into by throwing light to crucial areas like industry size, demand of the product and reasons for investing in the product.

• This report provides vital information on the product like its definition, characteristics and segmentation.

• This report helps you market and place the product correctly by identifying the target customer group of the product.

• This report helps you understand the viability of the project by disclosing details like raw materials required, manufacturing process, project costs and snapshot of other project financials.

• The report provides forecasts of key parameters which helps to anticipate the industry performance and make sound business decision.

 

Our Approach:


• Our research reports broadly cover Indian markets, present analysis, outlook and forecast.

• The market forecasts are developed on the basis of secondary research and are cross-validated through interactions with the industry players. 

• We use reliable sources of information and databases.  And information from such sources is processed by us and included in the report.

 

Our Market Survey cum Detailed Techno Economic Feasibility Report Contains following information:

 

 

Ø  Introduction

·         Project Introduction

·         Project Objective and Strategy

·         Concise History of the Product

·         Properties

·         BIS (Bureau of Indian Standards) Provision & Specification

·         Uses & Applications

 

Ø  Market Study and Assessment

·         Current Indian Market Scenario

·         Present Market Demand and Supply

·         Estimated Future Market Demand and Forecast

·         Statistics of Import & Export

·         Names & Addresses of Existing Units (Present Players)

·         Market Opportunity

 

Ø  Raw Material

·         List of Raw Materials

·         Properties of Raw Materials

·         Prescribed Quality of Raw Materials

·         List of Suppliers and Manufacturers

 

Ø  Personnel (Manpower) Requirements

·         Requirement of Staff & Labor (Skilled and Unskilled) Managerial, Technical, Office Staff and Marketing Personnel

 

Ø  Plant and Machinery

·         List of Plant & Machinery

·         Miscellaneous Items

·         Appliances & Equipments

·         Laboratory Equipments & Accessories

·         Electrification

·         Electric Load & Water

·         Maintenance Cost

·         Sources of Plant & Machinery (Suppliers and Manufacturers)

 

Ø  Manufacturing Process and Formulations

·         Detailed Process of Manufacture with Formulation

·         Packaging Required

·         Process Flow Sheet Diagram

 

Ø  Infrastructure and Utilities

·         Project Location

·         Requirement of Land Area

·         Rates of the Land

·         Built Up Area

·         Construction Schedule

·         Plant Layout and Requirement of Utilities

 

Project at a Glance

Along with financial details as under:

 

  •     Assumptions for Profitability workings

  •    Plant Economics

  •    Production Schedule

  •    Land & Building

            Factory Land & Building

            Site Development Expenses

  •    Plant & Machinery

             Indigenous Machineries

            Other Machineries (Miscellaneous, Laboratory etc.)

  •    Other Fixed Assets

            Furniture & Fixtures

            Pre-operative and Preliminary Expenses

            Technical Knowhow

            Provision of Contingencies

  •   Working Capital Requirement Per Month

             Raw Material

            Packing Material

            Lab & ETP Chemical Cost

           Consumable Store

  •   Overheads Required Per Month And Per Annum

         Utilities & Overheads (Power, Water and Fuel Expenses etc.)

             Royalty and Other Charges

            Selling and Distribution Expenses

  •    Salary and Wages

  •    Turnover Per Annum

  •   Share Capital

            Equity Capital

            Preference Share Capital

 

  •    Annexure 1:: Cost of Project and Means of Finance

  •    Annexure 2::  Profitability and Net Cash Accruals

                Revenue/Income/Realisation

                Expenses/Cost of Products/Services/Items

                Gross Profit

                Financial Charges     

                Total Cost of Sales

                Net Profit After Taxes

                Net Cash Accruals

  •   Annexure 3 :: Assessment of Working Capital requirements

                Current Assets

                Gross Working. Capital

                Current Liabilities

                Net Working Capital

                Working Note for Calculation of Work-in-process

  •    Annexure 4 :: Sources and Disposition of Funds

  •    Annexure 5 :: Projected Balance Sheets

                ROI (Average of Fixed Assets)

                RONW (Average of Share Capital)

                ROI (Average of Total Assets)

  •    Annexure 6 :: Profitability ratios

                D.S.C.R

                Earnings Per Share (EPS)

               

             Debt Equity Ratio

        Annexure 7   :: Break-Even Analysis

                Variable Cost & Expenses

                Semi-Var./Semi-Fixed Exp.

                Profit Volume Ratio (PVR)

                Fixed Expenses / Cost 

                B.E.P

  •   Annexure 8 to 11:: Sensitivity Analysis-Price/Volume

            Resultant N.P.B.T

            Resultant D.S.C.R

   Resultant PV Ratio

   Resultant DER

  Resultant ROI

          Resultant BEP

  •    Annexure 12 :: Shareholding Pattern and Stake Status

        Equity Capital

        Preference Share Capital

  •   Annexure 13 :: Quantitative Details-Output/Sales/Stocks

        Determined Capacity P.A of Products/Services

        Achievable Efficiency/Yield % of Products/Services/Items 

        Net Usable Load/Capacity of Products/Services/Items   

       Expected Sales/ Revenue/ Income of Products/ Services/ Items   

  •    Annexure 14 :: Product wise domestic Sales Realisation

  •    Annexure 15 :: Total Raw Material Cost

  •    Annexure 16 :: Raw Material Cost per unit

  •    Annexure 17 :: Total Lab & ETP Chemical Cost

  •    Annexure 18  :: Consumables, Store etc.,

  •    Annexure 19  :: Packing Material Cost

  •    Annexure 20  :: Packing Material Cost Per Unit

  •    Annexure 21 :: Employees Expenses

  •    Annexure 22 :: Fuel Expenses

  •    Annexure 23 :: Power/Electricity Expenses

  •    Annexure 24 :: Royalty & Other Charges

  •    Annexure 25 :: Repairs & Maintenance Exp.

  •    Annexure 26 :: Other Mfg. Expenses

  •    Annexure 27 :: Administration Expenses

  •    Annexure 28 :: Selling Expenses

  •    Annexure 29 :: Depreciation Charges – as per Books (Total)

  •   Annexure 30   :: Depreciation Charges – as per Books (P & M)

  •   Annexure 31   :: Depreciation Charges - As per IT Act WDV (Total)

  •   Annexure 32   :: Depreciation Charges - As per IT Act WDV (P & M)

  •   Annexure 33   :: Interest and Repayment - Term Loans

  •   Annexure 34   :: Tax on Profits

  •   Annexure 35   ::Projected Pay-Back Period And IRR